118 related articles for article (PubMed ID: 12459382)
1. Enhancement of vascular targeting by inhibitors of nitric oxide synthase.
Davis PD; Tozer GM; Naylor MA; Thomson P; Lewis G; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1532-6. PubMed ID: 12459382
[TBL] [Abstract][Full Text] [Related]
2. The development of combretastatin A4 phosphate as a vascular targeting agent.
Chaplin DJ; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
Tozer GM; Prise VE; Lewis G; Xie S; Wilson I; Hill SA
Clin Cancer Res; 2009 Jun; 15(11):3781-90. PubMed ID: 19470729
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Salmon BA; Siemann DW
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):211-7. PubMed ID: 17448875
[TBL] [Abstract][Full Text] [Related]
7. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM
Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
[TBL] [Abstract][Full Text] [Related]
8. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
Wachsberger PR; Burd R; Marero N; Daskalakis C; Ryan A; McCue P; Dicker AP
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):835-42. PubMed ID: 15701874
[TBL] [Abstract][Full Text] [Related]
9. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
10. Role of nitric oxide synthase isozymes in endotoxin-induced uveitis.
Mandai M; Mittag TW; Kogishi J; Iwaki M; Hangai M; Yoshimura N
Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):826-32. PubMed ID: 8603867
[TBL] [Abstract][Full Text] [Related]
11. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
13. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.
Ng QS; Goh V; Milner J; Stratford MR; Folkes LK; Tozer GM; Saunders MI; Hoskin PJ
Lancet Oncol; 2007 Feb; 8(2):111-8. PubMed ID: 17267325
[TBL] [Abstract][Full Text] [Related]
14. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
16. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
17. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
Salmon BA; Salmon HW; Siemann DW
Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
[TBL] [Abstract][Full Text] [Related]
19. The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.
Su J; Laursen BE; Eskildsen-Helmond Y; Horsman MR; Simonsen U
Eur J Pharmacol; 2012 Nov; 695(1-3):104-11. PubMed ID: 22981665
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.
Tozer GM; Prise VE; Chaplin DJ
Cancer Res; 1997 Mar; 57(5):948-55. PubMed ID: 9041200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
